MEIS1 and ovarian cancer: Indeed, MEIS1/2 can repress TGF-β type II receptor expression in lung cancer, a major molecular mechanism for inactivation of TGF-β-mediated tumor suppression5, and MEIS1/2 can be amplified and overexpressed in ovarian cancers compared with normal ovarian surface epithelium6,7.